Recent Updates
Recently added Catalysts
SKYE Neutral Sentiment

Obesity Through the Eyes of an Endocrinologist

Key Takeaway: The article titled 'Obesity Through the Eyes of an Endocrinologist' was published by Skye Bioscience on March 23, 2025. It appears to focus on the perspectives of an endocrinologist regarding obesity. However, the content does not provide specific insights or detailed information about the topic.
Price reaction · baseline $2.25 (2025-03-21 close) · clean, no other SKYE news in the window
day 0 close · peak
+4.4%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity

Full Press Release Details

Bioscience Bioscience Obesity Nasdaq: SKYE © 2026 Skye Bioscience. All Rights Reserved. All Primers Perspectives Progress Press Obesity Through the Eyes of an Endocrinologist Date published: March 23, 2025 7:37 pm PDT Share
Last updated: Mar 23, 2025